血管外科学会伤口、缺血和足部感染(WIfI)分类在无血运重建选择慢性肢体威胁性缺血患者中的预后价值
本研究基于JUVENTAS试验(单中心、双盲、随机安慰剂对照,N=160)的160例无血运重建选择慢性肢体威胁性缺血(CLTI)患者,回顾性分析150例的WIfI分期与临床结局关系。WIfI分期与伤口愈合、Rutherford分期改善、截肢率和长期死亡率相关;WIfI 2期患者6个月大截肢率反而劣于3期,其中7例截肢的2期患者有6例为W0-I3-fI0且缺血评分为3级。作者提出,对于无血运重建选择的典型缺血性静息痛(W0-I3-fI0)患者,肢体预后差,需进一步研究是否应将其从WIfI 2期重新归类为3期。
要点
- WIfI分期与无血运重建选择CLTI患者的伤口愈合、Rutherford分期改善、截肢率和长期死亡率相关。
- WIfI 2期患者6个月大截肢率劣于3期;7例截肢的2期患者中6例为W0-I3-fI0且缺血评分为3级。
- 将缺血性静息痛(W0-I3-fI0)重新归类为3期可改善该队列中WIfI分期对结局的区分度。
核心结论
- 本研究首次证明WIfI分类与无血运重建选择CLTI患者的重要临床结局相关。
- 数据提示,对于无血运重建选择的典型缺血性静息痛且无伤口或感染(W0-I3-fI0)患者,肢体预后差。
- 需进一步研究确定是否应将此类患者从WIfI 2期重新归类为3期,以反映无成功血运重建时的截肢风险。
研究设计与样本
- 基于JUVENTAS试验(单中心、双盲、随机安慰剂对照,研究自体骨髓单核细胞在无血运重建选择CLTI患者中的效果,N=160)的回顾性分析,纳入150例患者。
- 所有伤口在试验开始和结束时拍照并描述以进行WIfI分期,两名独立研究者回顾性按WIfI方案对所有肢体进行分类,并与前瞻性收集的试验数据关联。
- 采用Kaplan-Meier分析评估伤口愈合、临床改善、小截肢和大截肢率、无截肢生存率和死亡率等结局。
主要发现
- 150例患者中,Rutherford 4期占34%、5期占61%;WIfI 2期占33%、3期占21%、4期占35%。
- 糖尿病、肾功能受损和踝肱指数与WIfI分期独立相关。
- 单因素分析显示,WIfI分期与伤口愈合(P=0.001)、Rutherford分期改善(P=0.009)、截肢率(P<0.001)和长期死亡率(中位随访21.1个月,P=0.025)强烈相关。
- WIfI 2期患者6个月大截肢率劣于3期;7例截肢的2期患者中6例为W0-I3-fI0且缺血评分为最高3级。
- 将缺血性静息痛(W0-I3-fI0)重新归类为3期可改善并重排该队列中WIfI分期对结局的区分度。
局限性
- 需进一步研究确定是否应将无血运重建选择的缺血性静息痛(W0-I3-fI0)患者从WIfI 2期重新归类为3期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Wound, Ischemia, and foot Infection (WIfI) classification was developed to assess amputation risk and hence to aid in clinical decision-making in patients with chronic limb-threatening ischemia (CLTI). WIfI has been validated in multiple CLTI cohorts worldwide. In this study, we examined the relationship between WIfI stage and clinical outcomes in a well-defined subpopulation of CLTI patients considered not eligible for conventional revascularization. The aim of this study was to assess the prognostic value of the WIfI classification for clinical outcomes in a "no-option" CLTI population. METHODS: The Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial was a single-center, double-blinded, randomized placebo-controlled trial studying the effects of autologous bone marrow mononuclear cells in no-option CLTI patients (N = 160). We conducted a retrospective analysis incorporating baseline and follow-up data from the JUVENTAS trial. All wounds were photographed and described at the start and end of the trial to allow WIfI staging. Two independent researchers retrospectively classified all limbs according to the WIfI scheme, which was then related to prospectively collected trial data. Outcomes including wound healing, clinical improvement, minor and major amputation rate, amputation-free survival, and mortality were assessed using Kaplan-Meier analyses. RESULTS: Of the 160 patients, 150 could be included in this study. Most patients had been classified as Rutherford stage 4 (34%) and stage 5 (61%), with corresponding WIfI stage 2 (33%), stage 3 (21%), or stage 4 (35%). Diabetes, impaired renal function, and ankle-brachial index were independently associated with WIfI stage. On univariate analysis, WIfI stage was strongly associated with wound healing (P = .001), improvement of Rutherford stage (P = .009), amputation rate (P < .001), and long-term mortality (median follow-up, 21.1 months; P = .025). Of note, WIfI stage 2 patients had a worse 6-month major amputation rate compared with stage 3. Of the seven amputated stage 2 patients, six were in WIfI category W0-I3-fI0 and scored a maximum grade 3 on ischemia. Reclassification of ischemic rest pain (W0-I3-fI0) to stage 3 improved and reordered the discrimination of outcomes by WIfI stage in this cohort. CONCLUSIONS: This is the first study to demonstrate that WIfI classification is associated with important clinical outcomes in a no-option CLTI population. Our data suggest that limb prognosis is poor in patients with classic ischemic rest pain, without wounds or infection (W0-I3-fI0), when they lack revascularization options. Further studies are needed to determine whether reassignment of this population from WIfI stage 2 to WIfI stage 3 may be appropriate to reflect amputation risk in the absence of successful revascularization for patients suffering from ischemic rest pain in general.
引用
- van Haelst STW, Teraa M, Moll FL, et al. Prognostic value of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification in patients with no-option chronic limb-threatening ischemia. J Vasc Surg. 2018. PMID: 29802042. doi:10.1016/j.jvs.2018.02.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。